Form 4: Nurix Therapeutics CFO Hans van Houte Reports Sale of Common Stock

Hans van Houte, CFO of Nurix Therapeutics, reports the sale of 6,198 shares of common stock at an average price of $11.3331 on May 2, 2025, according to a Form 4 filing.

Summary

• On May 2, 2025, Hans van Houte, the Chief Financial Officer of Nurix Therapeutics, sold 6,198 shares of common stock.
• The sale was executed at a weighted average price of $11.3331 per share.
• The prices ranged from $11.195 to $11.55.
• Following the transaction, van Houte directly owns 33,724 shares of Nurix Therapeutics.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction under a pre-arranged trading plan. There's no indication of positive or negative implications for the company's outlook.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the use of a 10b5-1 plan can mitigate this concern.

Industry Context

Sales by company executives are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 plan is a standard practice to avoid insider trading accusations.

Comparison to Industry Standards

• Executive compensation packages often include stock options and grants, leading to periodic sales of shares.
• Companies like Amgen, Gilead, and Biogen also see regular Form 4 filings from their executives related to stock transactions.
• The volume and frequency of these transactions are generally in line with industry standards for companies of similar size and stage.

Stakeholder Impact

• The impact on stakeholders is likely minimal, as the sale was conducted under a pre-arranged trading plan and represents a small percentage of the company's outstanding shares.

Key Dates

Keywords

Form 4, Nurix Therapeutics, NRIX, Hans van Houte, CFO, Stock Sale, Rule 10b5-1, Insider Trading